KRAS and neoplasm: Results from ‘full’ Cox models including all candidate predictors (age, sex, tumour location, disease stage, primary tumour stage, BRAF mutation, KRAS mutation, MMR-D/POLE mutation, CIN, adjuvant chemotherapy, adjuvant bevacizumab and adjuvant rofecoxib), both before and after the addition of CD8+ cell density are provided in Table S5.